Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2019

Open Access 01-12-2019 | Addiction | Letter to the Editor

Is early detection of late-onset Pompe disease a pneumologist’s affair? A lesson from an Italian screening study

Authors: Marco Confalonieri, Michele Vitacca, Raffaele Scala, Mario Polverino, Eugenio Sabato, Grazia Crescimanno, Piero Ceriana, Caterina Antonaglia, Gabriele Siciliano, Nadja Ring, Serena Zacchigna, Francesco Salton, Andrea Vianello, on behalf of AIPO Pneumoloped Group

Published in: Orphanet Journal of Rare Diseases | Issue 1/2019

Login to get access

Abstract

Background

Late-onset Pompe disease (LOPD) is a recessive disease caused by α-glucosidase (GAA) deficiency, leading to progressive muscle weakness and/or respiratory failure in children and adults. Respiratory derangement can be the first indication of LOPD, but the diagnosis may be difficult for pneumologists. We hypothesize that assessing the GAA activity in suspected patients by a dried blood spot (DBS) may help the diagnosis of LOPD in the pneumological setting.

Population and methods

We performed a multicenter DBS survey of patients with suspected LOPD according to a predefined clinical algorithm. From February 2015 to December 2017, 140 patients (57 ± 16 yrs., 80 males) were recruited in 19 Italian pneumological units. The DBS test was performed by a drop of blood collected on absorbent paper. Patients with GAA activity < 2.6 μmol/L/h were considered positive. A second DBS test was performed in the patients positive to the first assay. Patients testing positive at the re-test underwent a skeletal muscle biopsy to determine the GAA enzymatic activity.

Results

75 recruited subjects had outpatient access, 65 subjects were admitted for an acute respiratory failure episode. Two patients tested positive in both the first and second DBS test (1.4% prevalence), and the LOPD diagnosis was confirmed through histology, with patients demonstrating a deficient GAA muscle activity (3.6 and 9.1 pmol/min/mg). A further five subjects were positive in the first DBS test but were not confirmed at re-test. The two positive cases were both diagnosed after hospitalization for acute respiratory failure and need of noninvasive ventilation. Most of the recruited patients had reduced maximal respiratory pressures (MIP 50 ± 27% and MEP 55 ± 27% predicted), restrictive pattern (FEV1/FVC 81.3 ± 13.6) and hypoxaemia (PaO2 70.9 ± 14.5 mmHg). Respiratory symptoms were present in all the patients, but only 48.6% of them showed muscle weakness in the pelvic girdle and/or in the scapular girdle (35.7%).

Conclusions

DBS GAA activity test may be a powerful screening tool among pneumologists, particularly in the acute setting. A simple clinical algorithm may aid in the selection of patients on which to administer the DBS test.
Literature
1.
go back to reference Raben N, Plotz P, Byrne BJ. Acid-alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med. 2002;2:145–66.CrossRef Raben N, Plotz P, Byrne BJ. Acid-alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med. 2002;2:145–66.CrossRef
2.
go back to reference Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease diagnosis and management guidelines. Genetics Med. 2006;8:267–88.CrossRef Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease diagnosis and management guidelines. Genetics Med. 2006;8:267–88.CrossRef
4.
go back to reference Chan J, Desai AK, Kazi ZB, Corey K, Austin S, Hobson-Webb LD, et al. The emerging phenotype of late-onset Pompe disease: a systematic literature review. Mol Gen Metabol. 2017;120:163–72.CrossRef Chan J, Desai AK, Kazi ZB, Corey K, Austin S, Hobson-Webb LD, et al. The emerging phenotype of late-onset Pompe disease: a systematic literature review. Mol Gen Metabol. 2017;120:163–72.CrossRef
5.
go back to reference Winkel LP, Hagemans ML, Van Doorn PA, Loonen MC, Hop WJ, Reuser AJ, et al. The natural course of non-classic Pompe’s disease; a review of 225 published cases. J Neurol. 2005;252:875–84. Winkel LP, Hagemans ML, Van Doorn PA, Loonen MC, Hop WJ, Reuser AJ, et al. The natural course of non-classic Pompe’s disease; a review of 225 published cases. J Neurol. 2005;252:875–84.
6.
go back to reference Mellies U, Lofaso F. Pompe disease: a neuromuscular disease with respiratory muscle involvement. Respir Med. 2009;103:477–84.CrossRef Mellies U, Lofaso F. Pompe disease: a neuromuscular disease with respiratory muscle involvement. Respir Med. 2009;103:477–84.CrossRef
7.
go back to reference Keunen RWM, Lambregts PCLA, Op de Coul AAW, Joosten EMG. Respiratory failure as initial symptom of acid maltase deficiency. J Neurol Neurosurg Psychiatry. 1984;47:549–52.CrossRef Keunen RWM, Lambregts PCLA, Op de Coul AAW, Joosten EMG. Respiratory failure as initial symptom of acid maltase deficiency. J Neurol Neurosurg Psychiatry. 1984;47:549–52.CrossRef
8.
go back to reference Menzella F, Codeluppi L, Lusuardi M, Galeone C, Valzania F, Facciolongo N. Acute respiratory failure as presentation of late-onset Pompe disease complicating the diagnostic process as a labyrinth: a case report. Multidiscip Respir Med. 2018;13:32.CrossRef Menzella F, Codeluppi L, Lusuardi M, Galeone C, Valzania F, Facciolongo N. Acute respiratory failure as presentation of late-onset Pompe disease complicating the diagnostic process as a labyrinth: a case report. Multidiscip Respir Med. 2018;13:32.CrossRef
9.
go back to reference Van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. A randomized study of alglucosidase alpha in late-onset Pompe’s disease. N Engl J Med. 2010;362:1396–406.CrossRef Van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. A randomized study of alglucosidase alpha in late-onset Pompe’s disease. N Engl J Med. 2010;362:1396–406.CrossRef
10.
go back to reference Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barhon NJ, et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve. 2012;45:319–33.CrossRef Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barhon NJ, et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve. 2012;45:319–33.CrossRef
11.
go back to reference Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, Chan K, et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol. 2017;264:621–30.CrossRef Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, Chan K, et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol. 2017;264:621–30.CrossRef
12.
go back to reference van der Ploeg A, Carlier PG, Carlier RY, Kissel JT, Schoser B, Wenninger S, et al. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: the EMBASSY study. Mol Genet Metab. 2016;119:115–23.CrossRef van der Ploeg A, Carlier PG, Carlier RY, Kissel JT, Schoser B, Wenninger S, et al. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: the EMBASSY study. Mol Genet Metab. 2016;119:115–23.CrossRef
13.
go back to reference Musumeci O, la Marca G, Spada M, Mondello S, Danesino C, Comi GP, et al. LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population. J Neurol Neurosurg Psychiatry. 2016;87:5–11.PubMed Musumeci O, la Marca G, Spada M, Mondello S, Danesino C, Comi GP, et al. LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population. J Neurol Neurosurg Psychiatry. 2016;87:5–11.PubMed
14.
go back to reference Ambrosino N, Confalonieri M, Crescimanno G, Vianello A, Vitacca M. The role of respiratory management of Pompe disease. Respir Med. 2013;107:1124–32.CrossRef Ambrosino N, Confalonieri M, Crescimanno G, Vianello A, Vitacca M. The role of respiratory management of Pompe disease. Respir Med. 2013;107:1124–32.CrossRef
15.
go back to reference Zhang H, Kallwas H, Young SP, Carr C, Dai J, Kishnani PS, et al. Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in dried blood spots for the diagnosis of infantile Pompe disease. Genet Med Dis. 2006;8:302–6.CrossRef Zhang H, Kallwas H, Young SP, Carr C, Dai J, Kishnani PS, et al. Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in dried blood spots for the diagnosis of infantile Pompe disease. Genet Med Dis. 2006;8:302–6.CrossRef
16.
go back to reference Hagemans MLC, Winkel LPF, Van Doorn PA, Hop WJ, Loonen MC, Reuser AJ, et al. Clinical manifestation and natural course of late-onset Pompe’s disease in 54 Dutch patients. Brain. 2005;128(Pt 3):671–7.CrossRef Hagemans MLC, Winkel LPF, Van Doorn PA, Hop WJ, Loonen MC, Reuser AJ, et al. Clinical manifestation and natural course of late-onset Pompe’s disease in 54 Dutch patients. Brain. 2005;128(Pt 3):671–7.CrossRef
17.
go back to reference Muller-Felber W, Horvath R, Gempel K, Podskarbi T, Shin Y, Pongratz D, et al. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long- term follow-up in 18 patients. Neuromuscul Disord. 2007;17:698–706.CrossRef Muller-Felber W, Horvath R, Gempel K, Podskarbi T, Shin Y, Pongratz D, et al. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long- term follow-up in 18 patients. Neuromuscul Disord. 2007;17:698–706.CrossRef
18.
go back to reference American Association of Neuromuscular & Electrodiagnostic Medicine. Diagnostic criteria for late-onset (childhood and adult) Pompe disease. Muscle Nerve. 2009;40:149–60.CrossRef American Association of Neuromuscular & Electrodiagnostic Medicine. Diagnostic criteria for late-onset (childhood and adult) Pompe disease. Muscle Nerve. 2009;40:149–60.CrossRef
19.
go back to reference Kishnani PS, Amartino HM, Lindberg C, Miller TM, Wilson A, Keutzer J. Timing of diagnosis of patients with Pompe disease: data from the Pompe registry. Am J Genet A. 2013;161:2431–43. Kishnani PS, Amartino HM, Lindberg C, Miller TM, Wilson A, Keutzer J. Timing of diagnosis of patients with Pompe disease: data from the Pompe registry. Am J Genet A. 2013;161:2431–43.
20.
go back to reference Scala R, Corrado A, Confalonieri M, et al. Increased number and expertise of Italian respiratory high-dependency care units: the second national survey. Respir Care. 2011;56:1100–7.CrossRef Scala R, Corrado A, Confalonieri M, et al. Increased number and expertise of Italian respiratory high-dependency care units: the second national survey. Respir Care. 2011;56:1100–7.CrossRef
Metadata
Title
Is early detection of late-onset Pompe disease a pneumologist’s affair? A lesson from an Italian screening study
Authors
Marco Confalonieri
Michele Vitacca
Raffaele Scala
Mario Polverino
Eugenio Sabato
Grazia Crescimanno
Piero Ceriana
Caterina Antonaglia
Gabriele Siciliano
Nadja Ring
Serena Zacchigna
Francesco Salton
Andrea Vianello
on behalf of AIPO Pneumoloped Group
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2019
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-019-1037-1

Other articles of this Issue 1/2019

Orphanet Journal of Rare Diseases 1/2019 Go to the issue